Hoth Therapeutics Inc (HOTH)

$0.58 +0.02 (3.04%)
Market Cap 9.14M
Revenue (ttm) 0.00
Net Income (ttm) -12.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 495,400
Avg Vol 517,220
Day's Range N/A - N/A
Shares Out 16.26M
Stochastic %K 18%
Beta 0.60
Analysts Strong Sell
Price Target $4.50

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 756 2997
Address:
1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States
Magic_Money_Mike
Magic_Money_Mike Apr. 7 at 4:12 AM
$HOTH
0 · Reply
Johnnyb1973
Johnnyb1973 Apr. 6 at 4:58 PM
$HOTH Well be back over a dollar within a month. 🤜💎🤛
0 · Reply
KOWALSK1
KOWALSK1 Apr. 6 at 3:30 PM
$HOTH another one today
0 · Reply
BullBobo
BullBobo Apr. 6 at 1:55 PM
$HOTH is sitting on a goldmine right now - Warrants for $0.85 is free money
0 · Reply
Adorno99
Adorno99 Apr. 6 at 12:07 AM
$HOTH warrant exercisable at 85 cents. Hold onto your shares!
0 · Reply
Tino321
Tino321 Apr. 3 at 5:31 AM
$HOTH $HOTH got 10k shares ready to buy Friday morning. We are balls deep in this play
1 · Reply
MrTicker
MrTicker Apr. 2 at 8:06 PM
$HOTH https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-closing-of-2-0-million-registered-direct-offering-302733218.html
0 · Reply
MrTicker
MrTicker Apr. 2 at 8:05 PM
$HOTH Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR NEWSWIRE 3:05 PM ET 4/2/2026
0 · Reply
Adorno99
Adorno99 Apr. 2 at 6:09 PM
$HOTH if you're a penny flipper at least wait until 90 cents. All others hold on for 3 bucks!
0 · Reply
Magic_Money_Mike
Magic_Money_Mike Apr. 2 at 5:19 PM
$HOTH $2 per share in 2027, buy.
1 · Reply
Latest News on HOTH
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Apr 2, 2026, 4:05 PM EDT - 4 days ago

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Apr 1, 2026, 1:52 PM EDT - 5 days ago

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Apr 1, 2026, 8:14 AM EDT - 5 days ago

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Mar 31, 2026, 8:07 AM EDT - 6 days ago

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

Mar 26, 2026, 8:30 AM EDT - 11 days ago

Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Mar 24, 2026, 8:13 AM EDT - 13 days ago

Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Mar 10, 2026, 8:13 AM EDT - 27 days ago

Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Mar 4, 2026, 8:31 AM EST - 4 weeks ago

Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Feb 24, 2026, 4:15 PM EST - 5 weeks ago

HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Feb 10, 2026, 8:30 AM EST - 7 weeks ago

Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study

Feb 10, 2026, 8:01 AM EST - 7 weeks ago

EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Feb 5, 2026, 8:03 AM EST - 2 months ago

Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Jan 22, 2026, 8:13 AM EST - 2 months ago

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Jan 21, 2026, 8:13 AM EST - 2 months ago

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Jan 15, 2026, 8:17 AM EST - 2 months ago

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Jan 2, 2026, 8:13 AM EST - 3 months ago

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Dec 3, 2025, 2:00 PM EST - 4 months ago

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Dec 1, 2025, 8:03 AM EST - 4 months ago

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Nov 20, 2025, 8:13 AM EST - 4 months ago

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Oct 27, 2025, 7:49 AM EDT - 5 months ago

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Oct 21, 2025, 8:23 AM EDT - 5 months ago

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Oct 8, 2025, 8:02 AM EDT - 6 months ago

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Oct 7, 2025, 7:57 AM EDT - 6 months ago

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Sep 24, 2025, 8:13 AM EDT - 6 months ago

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Sep 16, 2025, 8:14 AM EDT - 7 months ago

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Sep 10, 2025, 8:29 AM EDT - 7 months ago

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Sep 4, 2025, 8:16 AM EDT - 7 months ago

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Sep 2, 2025, 8:16 AM EDT - 7 months ago

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 29, 2025, 7:58 AM EDT - 8 months ago

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jul 22, 2025, 8:19 AM EDT - 9 months ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 10 months ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 24, 2025, 10:36 AM EDT - 10 months ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 23, 2025, 8:03 AM EDT - 10 months ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 1:34 PM EDT - 10 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 18, 2025, 8:22 AM EDT - 10 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 16, 2025, 8:00 AM EDT - 10 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 12, 2025, 9:17 AM EDT - 10 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 11, 2025, 8:28 AM EDT - 10 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 10 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

May 12, 2025, 7:30 AM EDT - 11 months ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 17, 2025, 8:01 AM EDT - 1 year ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 15, 2025, 8:19 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Apr 2, 2025, 7:58 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 31, 2025, 4:45 PM EDT - 1 year ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 26, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 18, 2025, 8:06 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 10, 2025, 8:02 AM EDT - 1 year ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 5, 2025, 1:40 PM EST - 1 year ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Mar 4, 2025, 8:16 AM EST - 1 year ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Magic_Money_Mike
Magic_Money_Mike Apr. 7 at 4:12 AM
$HOTH
0 · Reply
Johnnyb1973
Johnnyb1973 Apr. 6 at 4:58 PM
$HOTH Well be back over a dollar within a month. 🤜💎🤛
0 · Reply
KOWALSK1
KOWALSK1 Apr. 6 at 3:30 PM
$HOTH another one today
0 · Reply
BullBobo
BullBobo Apr. 6 at 1:55 PM
$HOTH is sitting on a goldmine right now - Warrants for $0.85 is free money
0 · Reply
Adorno99
Adorno99 Apr. 6 at 12:07 AM
$HOTH warrant exercisable at 85 cents. Hold onto your shares!
0 · Reply
Tino321
Tino321 Apr. 3 at 5:31 AM
$HOTH $HOTH got 10k shares ready to buy Friday morning. We are balls deep in this play
1 · Reply
MrTicker
MrTicker Apr. 2 at 8:06 PM
$HOTH https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-closing-of-2-0-million-registered-direct-offering-302733218.html
0 · Reply
MrTicker
MrTicker Apr. 2 at 8:05 PM
$HOTH Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR NEWSWIRE 3:05 PM ET 4/2/2026
0 · Reply
Adorno99
Adorno99 Apr. 2 at 6:09 PM
$HOTH if you're a penny flipper at least wait until 90 cents. All others hold on for 3 bucks!
0 · Reply
Magic_Money_Mike
Magic_Money_Mike Apr. 2 at 5:19 PM
$HOTH $2 per share in 2027, buy.
1 · Reply
banner20
banner20 Apr. 2 at 12:53 PM
$HOTH any upcoming news that can help.here. i like the pipeline
0 · Reply
Adorno99
Adorno99 Apr. 2 at 11:57 AM
$HOTH quite a HUGE bid there! 180k?
0 · Reply
KOWALSK1
KOWALSK1 Apr. 2 at 11:19 AM
$HOTH ✅️ BUY ZONE 0.54 to 0.50 ✋️ RISK BELOW 0.45 🎯 PT. 0.58 0.67 0.97 1.20 1.47 + UP Follow for more
0 · Reply
Bearbull_Baggins
Bearbull_Baggins Apr. 2 at 10:56 AM
$HOTH in for a swing at 57 cents after failing to commit to a buy for the past month at a dollar, will average down as needed. Glad I was hesitatant before. Must have been a sign
0 · Reply
Johnnyb1973
Johnnyb1973 Apr. 2 at 10:14 AM
$HOTH Its a 1/8 dilution is what it is. That brings the 5 dollar target to 4.375. Thats a 8x from where were at currently. 8x is huge to me! Fuck if it goes 3x that would be amazing and that's on the extreme low end of predictions. 🤜💎🤛 Stay strong my friends! Our day will come!
0 · Reply
Adorno99
Adorno99 Apr. 2 at 10:09 AM
$HOTH Can't buy until 7am but if they hold it under 60 until then I'm up for more!
0 · Reply
Barryman1
Barryman1 Apr. 2 at 8:15 AM
$HOTH I m buying till this hits 5$ 😀
0 · Reply
Kri81
Kri81 Apr. 2 at 2:09 AM
$HOTH Hwo likes Pink floyd?
1 · Reply
Kri81
Kri81 Apr. 2 at 12:38 AM
$HOTH my teori is that we burned down a lot of stop losses. Whats your teori of this breakdown?
1 · Reply
Magic_Money_Mike
Magic_Money_Mike Apr. 2 at 12:17 AM
$HOTH Buy, a lot. 🔥
1 · Reply
Kri81
Kri81 Apr. 2 at 12:14 AM
$HOTH most of you will sell before 5, i want to constran my self and hold. if so, i go to retirement. Even 10 is possible, and beyond
0 · Reply
Adorno99
Adorno99 Apr. 1 at 11:58 PM
$HOTH I don't understand why anyone would sell tonight.
0 · Reply